Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Santhera, Takeda deal

Santhera said it regained from Takeda exclusive, European and Swiss marketing rights to Catena idebenone for Duchenne muscular dystrophy (DMD), which Santhera granted Takeda in a 2007

Read the full 276 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE